published meta-analysis   sensitivity analysis   studies

control in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsREMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10] 1.10[0.58; 2.10]REMAP-CAP, shock-dependent course, 202010%240NAnot evaluable deathsdetailed resultsREMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53] 0.98[0.63; 1.53]REMAP-CAP, shock-dependent course, 202010%260NAnot evaluable deaths (time to event analysis only)detailed resultsREMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53] 0.98[0.63; 1.53]REMAP-CAP, shock-dependent course, 202010%260NAnot evaluable clinical improvementdetailed resultsREMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95] 1.22[0.76; 1.95]REMAP-CAP, shock-dependent course, 202010%260NAnot evaluable clinical improvement (14-day)detailed resultsREMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64] 1.03[0.65; 1.64]REMAP-CAP, shock-dependent course, 202010%260NAnot evaluable death or ventilationdetailed resultsREMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78] 1.24[0.55; 2.78]REMAP-CAP, shock-dependent course, 202010%118NAnot evaluable serious adverse eventsdetailed resultsREMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96] 3.68[0.42; 31.96]REMAP-CAP, shock-dependent course, 202010%242NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-28 21:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 649,650,589,651,968 - roots T: 290